Journey Medical Corporation: Form 8-K Summary
Business Context and Reporting Period
Journey Medical Corporation filed a Current Report on Form 8-K covering events occurring on January 12, 2022; the report was signed January 13, 2022. The filing concerns the acquisition of VYNE Therapeutics’ Molecule Stabilizing Technology franchise and an expansion of Journey’s credit facility. Journey’s common stock trades on the Nasdaq Capital Market under the symbol DERM.
Transaction and Key Financial Terms
- Journey acquired rights to the AMZEEQ and ZILXI FDA-approved products, the development-stage FCD105 program, and the Molecule Stabilizing Technology proprietary platform.
- Upfront consideration was $20.0 million, with an additional $5.0 million payment due on the first anniversary of closing.
- Contingent net-sales milestone payments may total up to $450.0 million, based on annual sales thresholds from $100 million to $500 million, calculated per product.
- Journey must pay VYNE 10% of certain upfront payments received from licensees or sublicensees for territories outside the United States, subject to exceptions in the Asset Purchase Agreement.
- The acquisition closed simultaneously with execution of the agreement.
Financing and Liquidity
- Journey amended its East West Bank credit facility, expanding total commitments to $30.0 million.
- The revolving facility increased from $7.5 million to $10.0 million.
- The amendment added a $20.0 million term loan: $15.0 million available at closing and an additional $5.0 million available through June 2023.
- The term loan has a four-year term, including two years of interest-only payments.
- Proceeds are intended to finance the acquisition and provide additional working capital.
- The filing does not provide interest rates, outstanding borrowings, cash balances, debt covenants, or utilization of the expanded facility.
Material Changes, Outlook, and Risks
- The acquisition materially expands Journey’s commercial product portfolio and adds a development-stage dermatology asset and proprietary technology platform.
- Journey became the plaintiff in pending patent litigation against Padagis Israel Pharmaceuticals concerning alleged infringement of patents covering AMZEEQ.
- Padagis submitted an abbreviated new drug application seeking approval for a generic version of AMZEEQ and alleges that the relevant patents are invalid.
- A 30-month stay currently prevents Padagis from selling a generic product, but the stay is scheduled to expire on December 30, 2023.
- Journey is seeking to prevent FDA approval from becoming effective before expiration of the listed AMZEEQ patents; the latest referenced patent expiration is September 8, 2037.
- Trial was scheduled for July 10, 2023. Journey stated that it could not predict the outcome or timing of the litigation.
- The filing provides no revenue, profit, cash-flow, margin, or other operating results for the reporting period, and no updated financial guidance.
Most Important Facts to Verify
- Review the complete Asset Purchase Agreement for purchase-price adjustments, milestone definitions, royalty or licensing provisions, and omitted confidential terms.
- Confirm the accounting treatment, purchase-price allocation, impairment risks, and expected contribution of AMZEEQ, ZILXI, FCD105, and the technology platform.
- Verify the final terms, interest rate, collateral, covenants, and borrowing status of the expanded East West Bank facility.
- Monitor the AMZEEQ patent litigation, including the July 2023 trial status and the December 30, 2023 stay expiration.
- Assess potential generic competition, FDA approval timing, and the enforceability and expiration dates of the AMZEEQ patents.